A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus
•A near full-length HCV amplicon was generated using a single set of primers.•HCV genotype 1a, 1b, 2b, 3a, 3b, 3h, 4a, 4d, 4o, 4r samples were sequenced.•Samples with HCV RNA down to 4 Log IU/mL were sequenced.•Method generated variation was estimated below 1%.•The method identified dual infections...
Saved in:
Published in | Journal of clinical virology Vol. 105; pp. 49 - 56 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.08.2018
|
Subjects | |
Online Access | Get full text |
ISSN | 1386-6532 1873-5967 1873-5967 |
DOI | 10.1016/j.jcv.2018.05.012 |
Cover
Summary: | •A near full-length HCV amplicon was generated using a single set of primers.•HCV genotype 1a, 1b, 2b, 3a, 3b, 3h, 4a, 4d, 4o, 4r samples were sequenced.•Samples with HCV RNA down to 4 Log IU/mL were sequenced.•Method generated variation was estimated below 1%.•The method identified dual infections and the presence of subgenomic replicons.
The current treatment options for hepatitis C virus (HCV), based on direct acting antivirals (DAA), are dependent on virus genotype and previous treatment experience. Treatment failures have been associated with detection of resistance-associated substitutions (RASs) in the DAA targets of HCV, the NS3, NS5A and NS5 B proteins.
To develop a next generation sequencing based method that provides genotype and detection of HCV NS3, NS5A, and NS5 B RASs without prior knowledge of sample genotype.
In total, 101 residual plasma samples from patients with HCV covering 10 different viral subtypes across 4 genotypes with viral loads of 3.84-7.61 Log IU/mL were included. All samples were de-identified and consequently prior treatment status for patients was unknown. Almost full open reading frame amplicons (∼ 9 kb) were generated using RT-PCR with a single primer set. The resulting amplicons were sequenced with high throughput sequencing and analysed using an in-house developed script for detecting RASs.
The method successfully amplified and sequenced 94% (95/101) of samples with an average coverage of 14,035; four of six failed samples were genotype 4a. Samples analysed twice yielded reproducible nucleotide frequencies across all sites. RASs were detected in 21/95 (22%) samples at a 15% threshold. The method identified one patient infected with two genotype 2b variants, and the presence of subgenomic deletion variants in 8 (8.4%) of 95 successfully sequenced samples.
The presented method may provide identification of HCV genotype, RASs detection, and detect multiple HCV infection without prior knowledge of sample genotype. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1386-6532 1873-5967 1873-5967 |
DOI: | 10.1016/j.jcv.2018.05.012 |